Search Results

aggressive (acute myeloid leukemia [AML]). Clinical and biological complexity has become apparent in this spectrum of disorders. To help to more clearly define the clinical status, prognosis, and therapeutic strategies for these patients, several clinical

know that Black and Hispanic patients with acute myeloid leukemia have higher mortality rates that are reliably predicted by census tract measures and treatment patterns. 9 A strictly utilitarian approach to allocation of vincristine based only on

following topics: Acute Myeloid Leukemia (AML) Breast Cancer Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Colon Cancer Gastric Cancer Hairy Cell Leukemia Head and Neck Cancers Hodgkin Lymphoma Melanoma (Cutaneous) Multiple Myeloma Non

therapeutic options in acute lymphoblastic leukemia, evolving concepts in the diagnosis and staging of multiple myeloma, advances in acute myeloid leukemia management, and emerging therapeutic options in acute lymphoblastic leukemia, among others. The

past year included updates to most patient guidelines, plus new booklets for: Acute Myeloid Leukemia Liver, Gallbladder, and Bile Duct (Hepatobiliary) Cancers Uterine (Endometrial) Cancer Neuroendocrine Tumors Oral Cancers Looking Ahead In the year

following types of cancer: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Breast Chronic Myeloid Leukemia Colorectal Head and Neck Kidney Lung Melanoma Multiple Myeloma Ovarian Prostate Urothelial Carcinoma New

appropriate. For example, allo-HCT may be considered the standard of care for some diseases (eg, acute myeloid leukemia [AML] or myelodysplastic syndromes [MDS]), whereas in others it may be considered developmental and ideally offered in the context of a

-HCT to be performed in patients previously considered ineligible. Although most studies comparing the results of myeloablative with reduced-intensity conditioning are limited to patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS

mutations contribute to the development and clinical outcomes of MDS, including their propensity to progress to more aggressive stages, such as acute myeloid leukemia (AML). Despite these findings, ambiguity remains about how best to use somatic mutations to

patients with APL. 1 SEER-17 data from 2001 to 2007 showed that APL represented 7.4% of all patients diagnosed with acute myeloid leukemia (AML), with an incidence rate of 2.7%. 2 Although the 5-year survival is higher in APL than in other AML subtypes